Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Ciprofloxacin

Generic name
Ciprofloxacin
Brand name
ATC Code
J01MA02

Pharmacokinetics in children

The following kinetic parameters have been observed (Aggarwal, Lipman, Peltola, Rubio and Zhao):

  Age Dose Cmax ss (mg/l) T½ ss (hours) Cl (l/hour/kg) V (l/kg)
ORAL > 3 months to 7 years 30 mg/kg 1.95-3.57 4.2-5.1 0.98-1.46 -
  5-17 years with CF 40 mg/kg 3.4-4.4 3.3-3.6 0.98-1.23 -
IV 0-3 months 20 mg/kg 2.3-3 - 0.04-0.81 0.4-3.55
  >3 months to 5 years 20 mg/kg 5.81-9.03 2.82-4.23 0.49-0.68 1.43-2.06
  5-17 years with CF 30 mg/kg 3.6-5.5 2.6-2.8 0.81-0.91 -

From the study by Payen et al. (N=55, 1 day – 24 years) it can be seen that the clearance in CF children is about twice as high as that in non-CF children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Complicated urinary tract infections, pyelonephritis, sepsis and febrile neutropenia
  • Oral
    • 1 month up to 18 years
      [14] [15] [27] [28]
      • 30 mg/kg/day in 2 doses. Max: 1.500 mg/day.
      • Duration of treatment:

        see the treatment protocol for each indication. The duration of treatment can vary from 7-21 days.

  • Intravenous
    • Premature infants Postmenstrual age < 34 weeks
      [24]
      • 15 mg/kg/day in 2 doses.

      • The scientific foundations for using ciprofloxacin in premature infants are limited; this dosage is based on a population pharmacokinetics model (Zhao).

    • Premature infants Postmenstrual age ≥ 34 weeks
      [24]
      • 25 mg/kg/day in 2 doses.

      • The scientific foundations for using ciprofloxacin in premature infants are limited; this dosage is based on a population pharmacokinetics model (Zhao).

    • 1 month up to 18 years
      [14] [15] [27] [28]
      • 20 - 30 mg/kg/day in 2 - 3 doses. Max: 1.200 mg/day. Max single dose: 400 mg/dose.
      • Duration of treatment:

        see the treatment protocol for each indication. The duration of treatment can vary from 7-21 days.
Bronchopulmonary infections in cystic fibrosis, caused by Pseudomonas aeruginosa
  • Oral
    • 1 month up to 18 years
      [4] [18] [19] [25]
      • 40 mg/kg/day in 2 doses. Max: 2.000 mg/day.
      • Duration of treatment:

        See treatment protocol. The duration of treatment can vary from 10-21 days

  • Intravenous
    • 1 month up to 18 years
      [4] [18] [19] [25]
      • 30 mg/kg/day in 2 - 3 doses. Max: 1.200 mg/day.
      • Duration of treatment:

        See treatment protocol. The duration of treatment can vary from 10-14 days; switch to oral administration in sequential treatment after a number of days
Selective bowel decontamination for immunocompromised patients with aplasia
  • Oral
  • Intravenous
    • 1 month up to 18 years
      [14] [15]
      • 30 mg/kg/day in 2 doses. Max: 800 mg/day. Max single dose: 400 mg/dose.
Post-exposure prophylaxis and treatment of anthrax
  • Oral
    • 1 month up to 18 years
      [9] [10] [13] [27]
      • 30 mg/kg/day in 2 doses. Max: 1.000 mg/day.
      • Duration of treatment:

        See the treatment protocol: often 60 days in a proven B. anthracis infection. Stop the prophylaxis if B. anthracis is not demonstrably present.

  • Intravenous
    • 1 month up to 18 years
      [9] [10] [13] [28]
      • 20 mg/kg/day in 2 doses. Max: 800 mg/day.
      • Duration of treatment:

        See the treatment protocol: often 60 days in a proven B. anthracis infection. Stop the prophylaxis if B. anthracis is not demonstrably present.
Perianal fistulae in Crohn’s disease
  • Oral
    • 1 month up to 18 years
      [26]
      • 20 mg/kg/day in 2 doses. Max: 1.000 mg/day.
Tularemia, plague
  • Oral
    • 1 month up to 18 years
      [29] [30]
      • 30 mg/kg/day in 2 doses. Max: 1.000 mg/day.
      • Duration of treatment:

        Plague: treatment 10 days; prophylaxis 7 days
        Tularemia: treatment at least 10 days, prophylaxis at least 14 days.

      • Tularemia: in a very large number of victims as a result of large-scale exposure and as post-exposure prophylaxis.

  • Intravenous
    • 1 month up to 18 years
      [29] [30]
      • 30 mg/kg/day in 2 doses. Max: 800 mg/day.
      • Duration of treatment:

        Plague: treatment 10 days;
        Tularemia: treatment at least 10 days.

      • Tularemia: in incidental cases or a limited number of victims as a result of a bioterrorist attack.
Infections (without clinical suspicion of meningitis) caused by microorganisms susceptible at increased exposure ('I')
  • Oral
  • Intravenous

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

Adjustment in renal impairment as specified:

GFR 50-80 ml/min/1.73 m2
Adjustment not necessary.
GFR 30-50 ml/min/1.73 m2
Dose adjustment not needed.
GFR 10-30 ml/min/1.73 m2
100 percentage of single dose and dosing interval : 24 uur
GFR < 10 ml/min/1.73 m2
100 percentage of single dose and dosing interval : 24 uur

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Gastrointestinal problems such as stomach pain, abdominal pain, anorexia, nausea, vomiting, diarrhoea, pseudomembranous colitis, dyspepsia, flatulence. Central side effects such as headaches, sleep disorders, dizziness, drowsiness, transpiration, paraesthesia, peripheral neuropathy, vision disorders, confusion, convulsions, restlessness, panic reaction, hallucinations, olfactory and colour vision and taste disturbances, anxiety, depression, tiredness. Arthralgia, arthropathy, hepatic and/or renal function disorders, thrombophlebitis, abnormal blood counts, tachycardia, hypotension, anaemia, asthenia, fever, pain in the extremities. Two cases of dental dyschromia have been described in the literature.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Slow infusion into a large vein or through a central line is desirable to minimize patient discomfort due to the low PH of the infusion solution and to reduce the risk of venous irritation.

Caution is needed when giving quinolones to children in the growth phase. Using them should be restricted to cases in which there are no other therapeutic possibilities.

In the primary healthcare sector, ciprofloxacin should not be given to children because of resistance issues.

Quinolones are known to trigger epileptic seizures or to lower the threshold for epileptic seizures. Ciprofloxacin must be used with caution in patients with conditions of the CNS that can have a tendency to cause epileptic seizures.

In experimental animal research, arthropathy was observed to a varying extent when very high doses were given to young dogs. These side effects have never been reported in humans either: fluoroquinolones are therefore being used to an increasing extend in children if there are no other therapeutic possibilities or if there are serious objections against the use of other broad-spectrum antibiotics.

Do not administer together with dairy product due to the interaction with calcum salts.
 

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Fluoroquinolones
J01MA12

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Aggarwal P, et al, Multiple dose pharmacokinetics of ciprofloxacin in preterm babies, Indian Pediatr., 2004, 41, 1001-7
  2. CBO, Richtlijn Diagnostiek en behandeling Cystic Fibrosis, www.cbo.nl, 2007
  3. Belet N, et al, Ciprofloxacin treatment in newborns with multi-drug-resistant nosocomial Pseudomonas infections., Biol Neonate., 2004, 85, 263-8
  4. Church DA, Sequential ciprofloxacin therapy in pediatric cystic fibrosis: Comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary, Pediatr Infect Dis J, 1997, 16, 97-105
  5. Chyský V, et al, Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation., Infection, 1991, 19, 289-96
  6. Drossou-Agakidou V, et al, Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year, Pediatr Infect Dis J, 2004, 23, 346-9
  7. Grady R, Safety profile of quinolone antibiotics in the pediatric population, Pediatr Infect Dis J, 2003, 22, 1128-32
  8. Hampel B, et al, Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use--safety report., Pediatr Infect Dis J, 1997, 16, 127-9
  9. Inglesby TV, et al, Anthrax as a biological weapon, 2002: updated recommendations for management, JAMA, 2002, 287, 2236-52
  10. Inglesby TV, et al, Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense, JAMA, 2000, May 3 283(17), 2281-90
  11. Koyle MA, et al, Pediatric urinary tract infections: the role of fluoroquinolones, Pediatr Infect Dis J, 2003, 22, 1133-7
  12. Lipman J, et al, Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?, Intensive Care Med., 2002, 28, 493-500
  13. Meyerhoff A, et al, US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax., Clin Infect Dis, 2004, 39, 303-8
  14. Mullen CA, Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients., Pediatr Infect Dis J, 2003, 22, 1138-42
  15. Paganini H, et al, Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia, Cancer., 2001, 91, 1563-7
  16. Peltola H, et al, Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children, Pediatrics, 1998, 101, 658-62
  17. Payen S, et al, Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections, Antimicrob Agents Chemother., 2003, 47, 3170-8
  18. Rubio TT, et al, Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation, Pediatr Infect Dis J, 1997, 16, 112-7
  19. Schaad UB, et al, Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis., Pediatr Infect Dis J., 1997, 16, 106-111
  20. van den Oever HL, et al, Ciprofloxacin in preterm neonates: case report and review of the literature, Eur J Pediatr, 1998, 157, 843-5
  21. R. Pieters, et al, Richtlijnen supportive care kinderoncologie Erasmus MC – Sophia Kinderziekenhuis., Geraadpleegd op 29 maart 2010, http://www.erasmusmc.nl/alkg-cs/242905/242981/supcare?version=1
  22. NHG, Standaard Urineweginfecties, H&W , 2005, 48, 341-53
  23. Van Pinxteren B et al, NHG Standaard Urineweginfecties (derde herziening), Huisarts Wet, 2013, 56(6), 270-80
  24. Zhao W et al, Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. , Antimicrob Agents Chemother., 2014, Nov;58(11), 6572-80
  25. Guillot E et al, Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis., Pharmacotherapy, 2010, Dec;30(12), 1252-8
  26. Ruemmele FM et al, Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease., J Crohns Colitis, 2014, Oct;8(10), 1179-207
  27. Bayer B.V., SmPC Ciproxin suspensie (RVG 19342) 01-08-2022, www.geneesmiddeleninformatiebank.nl
  28. Mylan BV, SmPC Ciprofloxacine infusie (RVG 29032) 27-11-2020, www.geneesmiddeleninformatiebank.nl
  29. LCI, Richtlijn tularemie (laatst gewijzigd 2017), http://www.rivm.nl/Onderwerpen/L/LCI_Richtlijnen
  30. LCI, Richtlijn pest (publicatiedatum 10-12-2013), http://www.rivm.nl/Onderwerpen/L/LCI_Richtlijnen
  31. Yildirim P., Association Patterns in Open Data to Explore Ciprofloxacin Adverse Events, Appl Clin Inform., 2015 Dec, 16;6(4), 728-47
  32. Hexal AG, SmPC CiproHEXAL Infusionslösung (58855.00.00/ 58856.00.00), 11/2015
  33. Fresenius Kabi Deutschland GmbH, SmPC Ciprofloxacin Kabi Infusionlösung (64688.00.00/ 64689.00.00/ 64690.00.00), 04/2017
  34. Hikma Pharma GmbH, SmPC Ciprofloxacin Hikma 2 mg/ml Infusionslösung (64983.00.00), 10/2014
  35. Bayer Vital GmbH, SmPC Ciprobay 400 mg (8242.05.02), 12/2015
  36. Bayer Vital GmbH, SmPC Ciprobay Saft 10% (36212.01.00), 05/2016
  37. Aliud Pharma GmbH, SmPC Ciprofloxacin AL (51992.00.00 / 51993.00.00 / 51993.01.00 / 51993.02.00), 03/2017
  38. Ratiopharm GmbH, SmPC Ciprofloxacin-ratiopharm 100/ 250/ 500/ 750 mg Filmtabletten (50514.00.00 / 50514.01.00 / 50514.02.00 / 50514.03.00), 11/2015
  39. Bayer Vital GmbH, SmPC Ciprobay 750 mg (8242.03.00), 12/2015
  40. Bayer Vital GmbH, SmPC Ciprobay 500 mg (8242.02.00), 12/2015
  41. Bayer Vital GmbH, SmPC Ciprobay 250 mg (8242.01.00), 12/2015
  42. Bayer Vital GmbH, SmPC Ciprobay Saft 5% (36212.00.00), 05/2016
  43. Bayer Vital GmbH, SmPC Ciprobay 200 mg (8242.04.02), 12/2015
  44. Bayer Int, DHPC Fluorochinolonen, 29 maart 2019
  45. BfArM., Rote-Hand-Brief zu Fluorchinolon-Antibiotika. 08.04.2019. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2019/rhb-fluorchinolone.pdf;jsessionid=4D7FF38A3DCDA1F9795930B56FD1B5E8.2_cid329?__blob=publicationFile&v=3, zuletzt aufgerufen am 12.04.2019.
  46. Dutch Working Party on Antibiotic Policy (SWAB) - Special Interest Group Pediatrics, Expert opinion on high dosing for infections caused by microorganisms susceptible to increased doses., Dec 6, 2022
  47. European Committee on Antimicrobial Susceptibility Testing - EUCAST, Clinical breakpoints - breakpoints and guidance, https://www.eucast.org/clinical_breakpoints, Jan2, 2023

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes